Medical Excellence Capital

John Prufeta, the founder and CEO, leads the firm alongside four other Managing Partners: Eric Heil, Kim Kamdar, Brian Halak, and Joni Mancini. The partnership blends operational health advisory experience with deep venture capital track records — Heil, Kamdar, and Halak all previously served as partners at Domain Associates, a life sciences venture fund with over $2.5 billion in managed capital.

The firm relies on the Medical Excellence Group, a private global health advisory chaired by Prufeta with offices in New York, Moscow, London, and Shanghai. This clinical network gives the venture fund direct lines to academic medical centers and practicing physicians who surface assets and validate therapeutic hypotheses before a formal financing process begins. MEC also creates companies internally — ProJenX, an ALS company, was co-created in partnership with Project ALS.

MEC is stage-agnostic within early-stage life sciences but concentrates heavily on therapeutics and enabling platform technologies. The active portfolio includes cell therapy (Aspen Neuroscience), small-molecule neurodegeneration (ProJenX), AI-driven rare disease discovery (Nobias Therapeutics), synthetic biology for stem cell engineering (GC Therapeutics), and next-generation diagnostics (Truvian Sciences, Pleno). Gene therapy and protein degradation (Avilar Therapeutics) also feature.

MEC is a venture capital firm that raises external limited partner capital, not a family office. However, its architecture mirrors a family-office operating company in that key functions — LP relations, clinical advisory services, and philanthropic grant-making — sit within a common ecosystem alongside the venture fund. The legal entities are distinct: MEC is the venture fund manager, and the Medical Excellence Foundation operates as a separate charitable organization.

Three of MEC’s managing partners — Eric Heil, Kim Kamdar, and Brian Halak — built their venture careers at Domain Associates, a life sciences fund where Kamdar and Halak remain partners managing existing Domain funds. MEC is an independent firm founded by John Prufeta in 2020; the Domain alumni joined to provide investment expertise, but MEC is not a spinout, successor, or affiliate of Domain.

John Prufeta co-founded the Medical Excellence Group in 2007 and chairs it; the firm operates as a global private health advisory with offices across four cities. The Medical Excellence Foundation is a separate 501(c)(3) that provides research grants to academic medical centers. MEC, the venture fund, was launched later and uses the advisory network’s clinical reach for deal sourcing and due-diligence, but the three entities are legally distinct.

The portfolio companies disclosed to date are headquartered in the United States, concentrated in biotech hubs such as San Diego, Philadelphia, and the Boston-Cambridge corridor. MEC’s lead partners are US-based, though the Medical Excellence Group’s international advisory presence in Moscow, London, and Shanghai could in principle surface cross-border opportunities.